dexamethasone prodrug (101-PGC-005) / 101 Therap - LARVOL DELTA

101-PGC-005 for the Treatment of COVID-19 (clinicaltrials.gov) - P2 | N=62 | Active, not recruiting | Sponsor: 101 Therapeutics | Phase classification: P2/3 ➔ P2 | N=329 ➔ 62

Enrollment change • Phase classification • Infectious Disease • Novel Coronavirus Disease • IL6

101-PGC-005 for the Treatment of COVID-19 (clinicaltrials.gov) - P2/3 | N=329 | Active, not recruiting | Sponsor: 101 Therapeutics | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • IL6

A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care (clinicaltrials.gov) - P2 | N=3 | Terminated | Sponsor: 101 Therapeutics | N=29 ➔ 3 | Trial completion date: Jun 2022 ➔ Feb 2023 | Recruiting ➔ Terminated | Trial primary completion date: Apr 2022 ➔ Feb 2023; Low Enrollment

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease

101-PGC-005 for the Treatment of COVID-19 (clinicaltrials.gov) - P2/3 | N=329 | Recruiting | Sponsor: 101 Therapeutics | Trial completion date: Mar 2023 ➔ Jun 2023

Trial completion date • Infectious Disease • Novel Coronavirus Disease • IL6

101-PGC-005 for the Treatment of COVID-19 (clinicaltrials.gov) - P2/3 | N=329 | Recruiting | Sponsor: 101 Therapeutics

New P2/3 trial • Infectious Disease • Novel Coronavirus Disease • IL6

Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects (clinicaltrials.gov) - P1 | N=6 | Active, not recruiting | Sponsor: 101 Therapeutics

New P1 trial • Infectious Disease • Novel Coronavirus Disease